Christine Miller, Humanity Changemaker

Meet Christine Miller – Christine is the President & CEO of Melinta Therapeutics.

Recently, the World Health Organization (WHO) declared antimicrobial resistance (AMR) as one of the top 10 global public health threats facing humanity. AMR infections disproportionately affect marginalized populations in low-resource settings, leading to even greater health and economic inequity. As President & CEO of Melinta Therapeutics, a commercial-stage company focused on the development and commercialization of novel antibiotics, Christine and her team are committed to providing innovative therapies to save lives and to make a meaningful impact to all people affected by AMR and other acute and life-threatening illnesses.

Before joining Melinta Therapeutics, Christine led the global and U.S. product portfolios for Sandoz, a $10 billion division of Novartis, where she was accountable for transitioning the portfolio toward rapid-growth and higher-margin segments. Throughout her career, Christine has directed more than 50 product launches that generated over $300 million of new annual revenue and has held positions at Actavis (now Allergan), Watson Pharmaceuticals, and Merck.

Christine also serves as an Advisory Board Member for the Healthcare Businesswomen’s Association.

#HumanityChangemakers amplifies the work of BIPOC and women innovators and disruptors in the healthcare industry. For more updates, follow us at Humanity Health!